USANA Health Sciences Inc. - 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 3, 2004, and the six months ended on that date. USANA Health Sciences, Inc. develops and manufactures nutritional and personal care products, distributed primarily through a network marketing system of independent "Associates" and directly to "Preferred Customers." The company operates two reportable segments: Direct Selling and Contract Manufacturing.
Key Financial Metrics
| Metric (in thousands) | Quarter Ended July 3, 2004 | Six Months Ended July 3, 2004 |
|---|---|---|
| Net Sales | $67,246 | $129,021 |
| Gross Profit | $51,051 | $97,768 |
| Gross Margin | 75.9% | 75.8% |
| Net Earnings | $7,413 | $13,626 |
| Diluted EPS | $0.36 | $0.66 |
| Cash and Equivalents | $13,798 | $13,798 (Ending Balance) |
| Operating Cash Flow (6mo) | N/A | $16,870 |
| Long-Term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 42.6% to $67.2 million for the quarter and 46.6% to $129.0 million for the six months compared to the prior year periods. Growth was driven by a 16.9% increase in the active Associate base, new market openings (South Korea, Singapore, Mexico), and favorable foreign currency translation.
- Profitability: Net earnings rose 70.5% to $7.4 million for the quarter and 72.0% to $13.6 million for the six months. Diluted EPS improved 80% to $0.36 for the quarter.
- Margins: Consolidated gross margin decreased slightly to 75.9% (from 77.9%) due to the lower-margin Contract Manufacturing segment. However, Direct Selling gross margin improved to 78.8%.
- Acquisitions: In February 2004, the company acquired FMG Productions, LLC for $2.14 million to enhance training and promotional materials for Associates.
- Share Repurchases: The company spent $14.9 million to repurchase 524,000 shares during the six-month period, significantly reducing cash balances.
Guidance, Outlook, and Risks
- Guidance: Management expects consolidated net sales to approach $69 million for the third quarter of 2004 and $270 million for the full fiscal year 2004. Diluted EPS is projected at $0.36 to $0.38 for the third quarter and $1.42 to $1.44 for the full year.
- Outlook: Contract Manufacturing sales are expected to be approximately $2.0 million in Q3. Selling, general, and administrative expenses are expected to rise slightly as a percentage of sales in Q3 due to the Annual International Convention.
- Risks: Key risks include reliance on the network marketing model, high Associate turnover, foreign currency fluctuations (53.8% of sales are international), and supply shortages for raw materials like CoQ10. The company has no outstanding debt but relies on a $10 million revolving credit facility for liquidity needs.
Investor Verification Checklist
- Verify the sustainability of the 16.9% growth in the active Associate base and the impact of new international markets (South Korea, Singapore, Mexico).
- Monitor the CoQ10 supply shortage and its potential to erode Direct Selling gross margins in future quarters.
- Assess the impact of the $14.9 million share repurchase on liquidity and the company's ability to fund future expansion without additional financing.
- Review the performance of the Contract Manufacturing segment, which currently operates at significantly lower margins (16.3%) than the core Direct Selling business.
- Confirm compliance with the restrictive covenants of the new $10 million credit facility entered into in June 2004.